Attached files
file | filename |
---|---|
8-K/A - 8-K/A - My Size, Inc. | zk1211057.htm |
EX-99.1 - EXHIBIT 99.1 - My Size, Inc. | exhibit_99-1.htm |
EX-23.1 - EXHIBIT 23.1 - My Size, Inc. | exhibit_23-1.htm |
EX-10.11 - EXHIBIT 10.13 - My Size, Inc. | exhibit_10-13.htm |
EX-10.18 - EXHIBIT 10.18 - My Size, Inc. | exhibit_10-18.htm |
EX-10.15 - EXHIBIT 10.15 - My Size, Inc. | exhibit_10-15.htm |
EX-10.12 - EXHIBIT 10.12 - My Size, Inc. | exhibit_10-12.htm |
EX-10.11 - EXHIBIT 10.11 - My Size, Inc. | exhibit_10-11.htm |
Exhibit 99.2
Pro Forma Financial Information.
Condensed Consolidated Pro Forma Unaudited Balance Sheet as of September 30, 2011
|
|
Condensed Consolidated Pro Forma Unaudited Statement of Operations for the Nine Months Ended September 30, 2011
|
|
Condensed Consolidated Pro Forma Unaudited Statement of Operations for the Year Ended December 31, 2010.
|
Unaudited Pro Forma Condensed Financial Information
On December 29, 2011, TopSpin, Inc. (the “Company”, “Registrant” or “TopSpin”) , entered into a Share Exchange Agreement (the “Agreement”) with Metamorefix, Ltd., an Israeli corporation (“Metamorefix”) and all of the shareholders of Metamorefix. Metamorefix is a company engaged in developing solutions for tissue regeneration, and skin tissue regeneration in particular.
Contemporaneously with the Agreement, the Company, together with the Company’s wholly-owned subsidiary Topspin Medical (Israel) Ltd. (the “Subsidiary”) and the other shareholders of Metamorefix, entered into an agreement for the purchase by the Subsidiary of 5,725,000 ordinary shares of Metamorefix, constituting 80.35% of the share capital of Metamorefix on an issued and outstanding basis (but not a fully diluted basis), in exchange for the Company issuing to the shareholders of Metamorefix (other than the Subsidiary) a total of 8,009,009 Ordinary Shares and the grant to the option holders of Metamorefix of 363,728 non-tradable options to purchase Ordinary Shares, constituting 40.49% of the Company`s share capital on a fully diluted basis.
Since the Registrant is a publicly registered corporation with no significant operations, Metamorefix will be treated as the continuing reporting entity. Accordingly, the transaction is accounted for as a recapitalization, equivalent to the issuance of stock by Metamorefix for the net monetary assets of the Registrant accompanied by a recapitalization.
The Pro forma Unaudited Financial Statements have been prepared by management of the Company in order to present consolidated financial position and results of operations of the Registrant and Metamorefix as if the acquisition had occurred as of September 30, 2011 for the pro forma condensed balance sheet and to give effect to the acquisition resulting in Metamorefix being the continuing reporting entity, as if the transaction had taken place at January 1, 2010 for the pro forma condensed consolidated statement of losses for the year ended December 31, 2010 and the nine months ended September 30, 2011.
The pro forma information is based on historical financial statements giving effect to the proposed transactions using the accounting treatment described above and the assumptions and adjustments in the accompanying notes to the pro forma financial statements. The unaudited pro forma financial information is not necessarily indicative of the actual results of operations or the financial position which would have been attained had the acquisitions been consummated at either of the foregoing dates or which may be attained in the future. The pro forma financial information should be read in conjunction with the historical financial statements of Metamorefix and Topspin (including notes thereto) included in the Form 8-K of which this pro forma financial information is a part.
CONSOLIDATED BALANCE SHEETS
NIS in thousands
METAMOREFIX LTD
CONDENSED CONSOLIDATED PRO FORMA UNAUDITED BALANCE SHEET
SEPTEMBER 30, 2011
Metamorefix September 30, 2011
|
TopSpin INC. September 30, 2011
|
Pro Forma Adjustments
|
Pro Forma Consolidated
|
||||||||||||||
Cash and cash equivalents
|
84 | - | 1,450 | 3 | 1,534 | ||||||||||||
Other accounts receivable and prepaid expenses
|
319 | 137 | - | 456 | |||||||||||||
Property and equipment, net
|
238 | - | - | 238 | |||||||||||||
Investment in affiliated company
|
- | 9,428 | (9,428 | ) 6 | - | ||||||||||||
Total Assets
|
641 | 9,565 | (7,978 | ) | 2,228 | ||||||||||||
Trade payables
|
101 | 1,415 | 1,516 | ||||||||||||||
Other accounts payable and accruals
|
108 | 644 | 300 | 4 | 1,052 | ||||||||||||
Shareholder's Loan
|
838 | 331 | (1,169 | ) 2 | - | ||||||||||||
Related parties
|
- | 150 | - | 150 | |||||||||||||
Accrued severance pay
|
26 | - | 26 | ||||||||||||||
Liability in respect of warrants
|
1,089 | - | 1,089 | ||||||||||||||
Tax provision
|
- | 1,312 | 1,312 | ||||||||||||||
Total liabilities
|
2,162 | 3,852 | (869 | ) | 5,145 | ||||||||||||
Share capital
|
71 | 43 | (29 | ) 1 | 85 | ||||||||||||
Additional paid in capital
|
8,871 | 182,788 | (186,546 | ) 5 | 7,761 | ||||||||||||
1,169 | 2 | ||||||||||||||||
1,450 | 3 | ||||||||||||||||
29 | 1 | ||||||||||||||||
Capital fund
|
- | 9,538 | (9,538 | ) 6 | - | ||||||||||||
Accumulated deficit
|
(10,463 | ) | (186,656 | ) | 186,656 | 5 | (10,763 | ) | |||||||||
(300 | ) 4 | ||||||||||||||||
Total Shareholders' Equity (Deficiency)
|
(1,521 | ) | 5,713 | (7,109 | ) | (2,917 | ) |
STATEMENTS OF OPERATIONS
NIS in thousands
METAMOREFIX LTD
CONDENSED CONSOLIDATED PRO FORMA UNAUDITED STATEMENT OF LOSSES
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2011
|
Metamorefix
September
30, 2011
|
TopSpin INC.
September
30, 2011
|
Pro Forma
Adjustments
|
Pro Forma
Consolidated
|
|||||||||||||
Research and development, net
|
844 | - | - | 844 | ||||||||||||
General and administrative
|
483 | 1,983 | (1,983 | ) 5 | 483 | |||||||||||
1,327 | 1,983 | (1,983 | ) | 1,327 | ||||||||||||
Financial expenses, net
|
19 | 131 | (131 | ) 5 | 19 | |||||||||||
Equity Loss in Subsidiary
|
- | 110 | (110 | ) 6 | - | |||||||||||
1,346 | 2,224 | (2,224 | ) 7 | 1,346 | ||||||||||||
(0.21 |
)
|
(0.07
|
)
|
(0.41 |
)
|
|||||||||||
Basic and diluted loss per ordinary share of NIS | (0.19 | ) | (0.22 | ) | (0.06 | ) | ||||||||||
Weighted average number of shares used to compute loss per share
|
7,125,000
|
9,958,328
|
7 |
20,668,852
|
STATEMENTS OF OPERATIONS
NIS in thousands
METAMOREFIX LTD
CONDENSED CONSOLIDATED PRO FORMA UNAUDITED STATEMENT OF LOSSES
FOR THE PERIOD ENDED DECEMBER 31, 2010
|
Metamorefix
December
31, 2010
|
TopSpin INC.
December
31, 2010
|
Pro Forma
Adjustments
|
Pro Forma
Consolidated
|
|||||||||||||||
Research and development, net
|
3,642 | - | - | 3,642 | ||||||||||||||
General and administrative
|
576 | 2,512 | (2,512 | ) 5 | 576 | |||||||||||||
4,218 | 2,512 | (2,512 | ) | 4,218 | ||||||||||||||
Financial expenses, net
|
485 | (197 | ) | 197 | 5 | 485 | ||||||||||||
4,703 | 2,315 | (2,315 | ) | 4,703 | ||||||||||||||
(0.21 | ) | (0.07 | ) | (0.41 | ) | |||||||||||||
Basic and diluted loss per ordinary share of NIS
|
(0.70 | ) | (1.52 | ) | (0.38 | ) | ||||||||||||
Weighted average number of shares used to compute loss per share
|
6,700,833
|
1,522,942
|
7 |
12,233,466
|
Pro Forma Adjustments
The following pro forma adjustments are incorporated into the pro forma condensed consolidated balance sheet as of September 30, 2011 and the pro forma condensed consolidated statement of losses for the nine months ended September 30, 2011 and the year ended December 31, 2010, respectively.
|
(1)
|
To record the total value of the shares after the transaction as 22,355,929 shares of Registrant’s newly issued shares of common stock; to eliminate Metamorefix capital structure; exchange 5,725,000 previously issued and outstanding shares of Metamorefix ordinary and preferred shares for 8,009,009 common shares of the Registrant.
|
|
(2)
|
To record issuance of 1,202,480 of the Registrant's shares of common stock in exchange to converting loans and accrued interest in amount of 1,169 thousand NIS .
|
|
(3)
|
To record the effect of an additional loan received from interested parties in conjunction with the overall Metamorfix transaction in the amount of 1,450 thousands NIS which was converted into 1,499,036 common shares of the Registrant.
|
|
(4)
|
To record 300 thousands NIS acquisition costs.
|
|
(5)
|
To eliminate Registrant’s expenses and accumulated deficit, and record recapitalization of Registrant.
|
|
(6)
|
To eliminate Metamorefix balances as an affiliated company in the Registrant’s balance.
|
|
(7)
|
The pro forma number of shares is based on the weighted average number of shares used to compute the historical loss per share of the registrant plus 10,710,524 shares representing the total number of shares issued upon the consummation of the Metamorifx transaction as described in adjustments (1), (2) and (3).
|